# Inmune Bio

Inmune Bio is an Asset Manager based in Boca Raton, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Boca Raton, United States
- **Region:** North America
- **Address:** Boca Raton, FL, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** inmunebio.com
- **LinkedIn:** https://www.linkedin.com/company/inmune-bio-inc

## Regulatory record

- **Reports private funds:** No

## About

INmune Bio is focused on modulating components of the innate immune system to activate an immune response to diseases. | INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.

## Sectors

- Digital Health
- Healthcare Services

## People

- RJ Tesi — Chief Executive Officer
- David Moss — Chief Financial Officer

## Questions

### What is Inmune Bio's lead drug candidate?

XPro1595 is a next-generation, selective tumor necrosis factor (TNF) inhibitor that targets soluble TNF while sparing transmembrane TNF. The company is evaluating it in Phase 2 trials for Alzheimer's disease and treatment-resistant depression, aiming to reduce neuroinflammation, a core driver of these conditions.

### How does Inmune Bio's approach to Alzheimer's differ from approved therapies?

Unlike anti-amyloid antibodies that clear plaque build-up, Inmune Bio targets neuroinflammation via soluble TNF neutralization. The scientific premise posits that chronic immune dysfunction within the brain contributes directly to the synaptic loss and cognitive decline seen in Alzheimer's, a hypothesis not addressed by current FDA-approved monoclonal antibodies.

### Does Inmune Bio have programs beyond Alzheimer's disease?

Yes. The XPro1595 platform is also being studied in treatment-resistant depression. Additionally, the company is developing INKmune, a biologic natural killer cell therapy designed to target both hematologic malignancies and solid tumors, providing a separate immuno-oncology pipeline.

### What is the mechanism of action for XPro1595?

XPro1595 is a dominant-negative TNF biologic — it works by selectively neutralizing soluble TNF, the form that drives chronic inflammation, without affecting transmembrane TNF, which is essential for immune surveillance and neuronal function. This selectivity is designed to maximize anti-inflammatory benefit while limiting immunosuppressive side effects common with broader TNF blockers.

## Related profiles

- [Mountain Crest Acquisition Corp. V](https://altss.com/profile/mountain-crest-acquisition-corp-v)
- [Family Office of America](https://altss.com/profile/family-office-of-america-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/inmune-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology